Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study,Arthritis & Rheumatology

当前位置： X-MOL 学术 › Arthritis Rheumatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study
Arthritis & Rheumatology ( IF 11.4 ) Pub Date : 2024-11-18 , DOI: 10.1002/art.43059
Thomas Dörner, Simon J. Bowman, Robert Fox, Xavier Mariette, Athena Papas, Thomas Grader-Beck, Benjamin A. Fisher, Filipe Barcelos, Salvatore De Vita, Hendrik Schulze-Koops, Robert J. Moots, Guido Junge, Janice Woznicki, Monika Sopala, Alexandre Avrameas, Wen-Lin Luo, Wolfgang Hueber

The objective of this study was to report 52-week safety and efficacy of ianalumab from phase 2b dose-finding study in patients with Sjögren's disease (SjD).

中文翻译：